Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Yescarta | axicabtagene ciloleucel | Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Bavencio | Avelumab | metastatic Merkel Cell Carcinoma (mMCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Bavencio | Avelumab | Urothelial Carcinoma (UC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Doptelet | avatrombopag | Chronic immune thrombocytopenia (ITP) | Active | |||
Doptelet | avatrombopag | severe thrombocytopenia associated with chronic liver disease (CLD) | Pending | |||
TBC | avapritinib | Advanced Systemic Mastocytosis | Active | |||
Nexviazyme | avalglucosidase alfa | Pompe disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Tavneos | avacopan | Antineutrophil cytoplasmic antibody-associated vasculitis | Do not reimburse | Complete | ||
Strattera | Atomoxetine hydrochloride | Attention deficit hyperactivity disorder | Do not list | Complete | ||
Strattera | Atomoxetine hydrochloride | Attention deficit hyperactivity disorder | N/A | Complete |